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Abstract
Introduction: New levels of gene regulation with microRNA (miR) and gene copy number alterations (CNAs) have
been identified as playing a role in various cancers. We have previously reported that sporadic breast cancer tissues
exhibit significant alteration in H2AX gene copy number. However, how CNA affects gene expression and what is
the role of miR, miR-24-2, known to regulate H2AX expression, in the background of the change in copy number,
are not known. Further, many miRs, including miR-24-2, are implicated as playing a role in cell proliferation and
apoptosis, but their specific target genes and the pathways contributing to them remain unexplored.
Methods: Changes in gene copy number and mRNA/miR expression were estimated using real-time polymerase
chain reaction assays in two mammalian cell lines, MCF-7 and HeLa, and in a set of sporadic breast cancer tissues.
In silico analysis was performed to find the putative target for miR-24-2. MCF-7 cells were transfected with
precursor miR-24-2 oligonucleotides, and the gene expression levels of BRCA1, BRCA2, ATM, MDM2, TP53, CHEK2,
CYT-C, BCL-2, H2AFX and P21 were examined using TaqMan gene expression assays. Apoptosis was measured by
flow cytometric detection using annexin V dye. A luciferase assay was performed to confirm BCL-2 as a valid
cellular target of miR-24-2.
Results: It was observed that H2AX gene expression was negatively correlated with miR-24-2 expression and not in
accordance with the gene copy number status, both in cell lines and in sporadic breast tumor tissues. Further, the
cells overexpressing miR-24-2 were observed to be hypersensitive to DNA damaging drugs, undergoing apoptotic
cell death, suggesting the potentiating effect of mir-24-2-mediated apoptotic induction in human cancer cell lines
treated with anticancer drugs. BCL-2 was identified as a novel cellular target of miR-24-2.
Conclusions: mir-24-2 is capable of inducing apoptosis by modulating different apoptotic pathways and targeting
BCL-2, an antiapoptotic gene. The study suggests that miR-24-2 is more effective in controlling H2AX gene
expression, regardless of the change in gene copy number. Further, the study indicates that combination therapy
with miR-24-2 along with an anticancer drug such as cisplatin could provide a new avenue in cancer therapy for
patients with tumors otherwise resistant to drugs.
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Copy number variations (CNVs) are ubiquitous in nat-
ure and have been identified in diverse species, includ-
ing humans [1], monkeys [2], rats [3], mice [4] and
Drosophila [5]. Advancement in DNA array technology
has led to the discovery of CNVs that are now believed
to cover at least 10% of the total human genome [6]. In
a short span of time since their discovery, CNVs have
been characterized and shown to play a role in a num-
ber of human diseases, including cancers. Among the
DNA repair genes, changes in gene copy numbers of
BRCA2 and H2AFX have been shown to be associated
with ovarian cancer [7] and breast cancer [8], respec-
tively. Although the importance of CNVs (in germline
cells) [9] or alterations (in somatic cells) [7,10] has been
uncovered in recent years, their molecular and cellular
consequences remain to be understood completely.
H2AX is a variant of histone H2A, and is rapidly
phosphorylated at serine 139 by members of the phos-
phatidyl inositol 3-kinase family of kinases [11,12] in
response to different cellular stressors, such as DNA
double-stranded breaks, osmotic stress, replication
blockage and hyperthermia [13-18]. In the past decade,
H2AX has generated much scientific interest, not only
because of its functional enormity but also because of
its localization in highly vulnerable cytogenetic regions,
such as 11q23.3, which is known to undergo frequent
alteration in most human cancers, including breast can-
cer [19-23]. The H2AX gene is not essential, but its
absence shows increased genomic instability and sensi-
tivity to DNA damaging agents [24,25]. Recently, the
microRNA (miR) miR-24-2 has been identified as a reg-
ulator of H2AX gene expression [26]. A large number of
studies have signified the important role of miR in cell
proliferation and apoptosis [27,28]. Some miRs, such as
miR-29b and miR-15-16, modulate the apoptotic path-
way, whereas a few others, including miR-24, let-7/miR-
98 and miR-17-92 have been shown to affect both the
apoptotic and cell proliferation pathways [29].
In the present study, we observed that regardless of
alterations in gene copy number, the expression of
H2AX is regulated by miR-24-2. MCF-7 and HeLa cells
were utilized as model cell lines, since the two showed
differential H2AFX gene copy numbers [8] and the find-
ings were then confirmed in a representative set of
breast carcinoma samples. miR-24-2 has been reported
to modulate the cell’s apoptotic response; however, the
only gene target identified with respect to apoptotic
function is Fas-associated factor 1 (FAF1) [30]. Our
study identifies the antiapoptotic gene BCL-2 as a novel
biological target of miR-24-2 and suggests that overex-
pression of miR-24-2 induces apoptosis by downregulat-
ing the expression of genes such as BCL-2, MDM-2,
H2AFX and P21.
Materials and methods
Cell culture
MCF-7 and HeLa cells were cultured in RPMI 1640
medium (Sigma, St. Louis, MO, USA). Media were sup-
plemented with 10% fetal bovine serum, 1 mmol/l L-
glutamine and 50 μg/ml penicillin/streptomycin.
Tumor samples
Tissue samples from patients with sporadic ductal breast
carcinoma were obtained from Dharamshilla Cancer
Hospital and Rajiv Gandhi Cancer Research Institute,
Delhi, India. Informed written consent following the
Indian Council of Medical Research norms was obtained
from all individuals, and the ethics committee of Jawa-
harlal Nehru University approved the study. Clinico-
pathological details were also obtained from the patients
with their consent.
Determination of H2AX copy number
The relative change of H2AX copy number between
normal and tumor pairs or different cell lines was deter-
mined by real-time polymerase chain reaction (RT-PCR)
assay following the comparative threshold cycle (Ct)
method [31]. The TaqMan assay(Applied Biosystems,
USA) used for H2AX was Hs01573336_s1. The target
g e n ea n dt h er e f e r e n c eg e n e( R N a s eP )w e r ea m p l i f i e d
separately using the ABI PRISM 7000 Sequence Detec-
tion System (PE Applied Biosystems, Foster City, CA,
USA). PCR was performed in a total volume of 25 μli n
each well, which contained 12.5 μl of TaqMan Universal
MasterMix (PE Applied Biosystems), 25 ng of genomic
DNA and a 12.5 picomoles per liter concentration of
each primer. PCR conditions included an initial dena-
turation step of 95°C for 10 minutes, followed by 40
cycles at 95°C for 15 seconds and 60°C for 1 minute. All
of the reactions were carried out in duplicate, and a
negative control with no template was kept with every
PCR run. For all PCR assays, Ct numbers were estab-
lished by using SDS 1.1 RQ software (Applied Biosys-
tems), and the copy number, normalized against a
r e f e r e n c eg e n e( R N a s eP ) ,a n dt h ec a l i b r a t o r( n o r m a l
sample of the respective pair) were determined by using
the formula 2
-ΔΔCt. A twofold increase or decrease in
the copy number of H2AX in tumor samples in compar-
ison to the corresponding normal sample within the pair
was considered as amplification or deletion, respectively.
RNA isolation and quantitative RT-PCR
Total RNA was extracted from tumor samples and cell
lines by using TRIzol reagent (Sigma) according to the
manufacturer’s instructions. RNA quality from each
sample was determined by the A260/A280 absorbance
ratio and by electrophoresis on 1.2% agarose formalde-
hyde gel. Quantities of 1.0 to 2.0 mg of total RNA were
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Omniscript Reverse Transcriptase kit (Qiagen, Hildane,
Germany). The commercially available TaqMan Gene
Expression Assay system (Applied Biosystems) was used
for quantitating transcription levels of H2AX, ATM,
T P 5 3 ,C H K - 2 ,B c l - 2 ,p 2 1 ,M D M 2 ,B R C A 1 ,B R C A 2a n d
CYT-C. Quantitative RT-PCR was carried out using an
ABI Prism 7000 Sequence Detection System (Applied
Biosystems). Ct numbers were established by using SDS
1.1 RQ software (Applied Biosystems), and ΔCt values
were determined (ΔCt = Ct of target gene - Ct of inter-
nal control) as raw data forg e n ee x p r e s s i o n .A l lt h e
reactions were carried out in duplicate, and fold changes
in gene expression were determined by using the for-
mula 2
-ΔΔCt. geNorm software [32] was used to establish
the two most stable internal control genes (MRPL19
and PUM1) from a group of four endogenous controls
(ACTIN, GAPDH, PUM1 and MRPL19), followed by the
calculation of the normalization factor for each tissue
sample.
Confocal microscopy and image capturing
Cells were grown on coverslips in Dulbecco’s modified
Eagle’s medium. At 70% confluence, the cells were fixed
in 4% paraformaldehyde for 30 minutes at room tem-
perature. The cells were then washed in phosphate-buf-
fered saline (PBS) thrice at 5-minute intervals and
processed for immunostaining. The cells were incubated
in blocking buffer for 1 hour at 37°C before overnight
incubation with rabbit polyclonal primary antibodies
(anti-H2AX and anti-g-H2AX; Bethyl Laboratories,
USA) at 4°C and diluted (1:500) in blocking buffer. Fol-
lowing 15-minute washes in PBS + 0.1% Triton X-100
(PBST) thrice, the signals were detected after incubation
with chicken anti-rabbit Alexa Fluor 488 ( Invitrogen,
Bangalore, India) diluted 1:1,000 at 37°C for 2 hours.
After 15-minute PBST washes thrice, the cells were
counterstained with propidium iodide (PI) along with
RNase (10 μg/ml PI and 200 μg/ml RNase A) treatment
for 7 to 10 minutes at 37°C and mounted in DABCO
(Sigma).
Image capturing
Stained cells were observed with a Nikon TE 2000E
microscope (Nikon, Japan) equipped with a ×60/1.4 NA
Plan-Apochromat (Carl Zeiss, NY, USA) DIC objective.
PI was excited at 543 nm with He-Ne laser and Alexa
Fluor 488 at 488 nm with an argon ion laser. The emis-
sions were recorded through an emission filter set 515/
30, 605/75. Images were acquired sequentially to avoid
bleed-through, with a scanning mode format of 512 ×
512 pixels. The transmission and detector gains were set
to achieve the best signal-to-noise ratios, and the laser
powers were tuned to limit bleaching of fluorescence.
T h er e f r a c t i v ei n d e xo ft h ei m m e r s i o no i lu s e dw a s
1.515 (Nikon). All settings were rigorously maintained
for all experiments.
All images were qualitatively assessed using Image Pro
Plus version 6.0 software (Media Cybernetics, Bethesda,
MD, USA). All the images were stored in Tiff RGB 24
format. To reduce the unwanted ground noise generated
by the photomultiplier signal amplification, the images
were treated with two-dimensional filters (Gaussian and
sharpening filtering).
In silico analysis
Many computational target prediction software plat-
forms have been developed to identify the miR binding
sites in 3’UTR of the of the gene transcripts. To avoid
spurious prediction, four widely used software platforms,
PicTar [33], miRBase Targets version 5 [34], TargetScan
[35] and microRNA[36], were used to perform the target
prediction. H2AFX transcription was predicted as a good
target for hsa-miR-24-2 by all four prediction software
types, and miR-24-2 was found to have two possible
binding sites in the 3’UTR of H2AX mRNA (Table S1
in Additional file 1). Microrna.org (miRanda algorithm)
predicted BCL2, while TargetScan predicted MDM2,a s
a target gene for miR-24-2. However, transcripts of
TP53, P21 and CYT-C were not detected by any of the
software platforms as targets of miR-24-2.
Transfection and miR assay
Transfection was performed using ESCORT transfection
reagent (Sigma). Synthetic pre-miR-24-2 oligonucleo-
tides (Ambion, Austin, TX, USA) or antagomir
(Ambion) were transfected at a final concentration of 50
nmol/l. Transfection with a pre-miR negative control
oligonucleotide (Ambion, PM 17001) was always used as
a negative control. Cells were harvested 48 hours after
transfection, and RNA was obtained using the mir-
Vana™ miRNA Isolation Kit (Ambion). The quantity
and quality of RNA were analyzed by Nanodrop (Nano-
Drop Technologies, Wilmington, DE, USA) using 260/
280 nm and gel analysis. TaqMan microRNA assays
(Applied Biosystems) that include specific RT primers
and TaqMan probes were used to quantify the expres-
sion of mature miR-24-2 (Assay ID 002441; PN
4427975), and RNU 44 (Assay ID 001094; PN 4427975)
was used for normalization.
Apoptosis assay
Apoptosis was measured by the flow cytometric detec-
tion of phosphatidylserine externalization using APC
Annexin V staining (BD Biosciences, MD, USA). MCF-7
cells, after transfection with pre-miR-24-2 and pre-miR
negative controls, were treated with 200 μmol/l cisplatin
for 24 hours (Sigma, Louis, MO, USA) and 25 mmol/l
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harvested and processed for APC Annexin V staining as
per the manufacturer’s protocol (BD Biosciences).
Briefly, cells were washed twice with binding buffer (10
mmol/l (4-(2-hydroxyethyl)-1-piperazineethanesulfonic
acid, 140 mmol/l NaCl and 5 mmol/l CaCl2,p H7 . 4 )
and stained with APC-conjugated annexin V for 15 min-
utes at room temperature, followed by flow cytometric
analysis using the Becton Dickinson FACSCalibur
(Franklin Lakes, NJ, USA). The extent of apoptosis was
quantified as the percentage of annexin V-positive cells.
Luciferase assay
Luciferase assay was performed to confirm the interac-
tion of miR-24-2 with the predicted binding sites of the
genes. The miR-24-2 predicted binding sites in the
3’UTR of the BCL2 and H2AFX genes were amplified by
using specific primers (Table S3 in Additional file 1),
and the amplicons were cloned at the 3’UTR of lucifer-
ase gene in pGL3 control vector. The positive clones
were confirmed by sequencing and then used for the
luciferase assay. The assay was performed in two differ-
ent mammalian cell lines, HepG2 and MCF-7, simulta-
neously. Briefly, cells were seeded in 12-well plates, and,
after 24 hours of growth, they were transfected with
specific sets of plasmid mix (pEP-miR-24-2 + pGL3-
BCL2/H2AFX+ pRL-TK) using ESCORTS reagent
(Sigma). A pEP-miR-24-2 vector (Cell Biolabs, San
Diego, CA, USA) was used to overexpress miR-24-2 in
cells. After 48 hours of transfection, cells were assayed
to measure firefly and Renilla luminescence using the
luciferase kit (Promega, Madison, WI, USA). The ratio
of firefly reporter and Renilla control reporter in the
presence of miR-24-2 was calculated and then used to
define the change in the expression of firefly reporter in
the co-presence of predicted binding sites of specific
genes and in the overexpression of miR-24-2.
Results
H2AFX gene copy number and transcript expression in
MCF-7 and HeLa cells
H2AFX gene copy number as measured by RT-PCR
assay using TaqMan chemistry revealed twofold dele-
tions in MCF-7 cells compared to HeLa cells (Figure
1a). To ascertain whether this change in copy number
brought about a corresponding change in gene expres-
sion, RT-PCR analysis of the transcripts was performed.
A sevenfold higher expression was observed in MCF-7
cells compared to the transcription level in HeLa cells
in a simultaneous study (Figure 1b). This noncorrespon-
dence of expression with the CNA was paradoxical.
Further confirmation of these observations in the two
cell lines, with a loss (MCF-7) but high transcription
expression and gain (HeLa) with a relatively low
expression, was carried out in in situ protein level
expression in a confocal study (Figure 1c). The presence
of an increased amount of the unphosphorylated form
of H2AX in MCF-7 nuclei and cytosol corroborated
with the higher expression of transcripts, despite low
CNA in the H2AFX gene. To establish whether the
increased H2AX staining was due to an inherent DNA
damage status of the MCF-7 cells used, two approaches
were adopted. First, serine 139 phosphorylation of the
H2AX protein (g-H2AX) serves as a very good marker
of DNA damage, and therefore we used phosphorylated
H2AX antibodies to detect the difference between phos-
phorylated and unphosphorylated forms of H2AX. Sec-
ond, we assessed the induction of g-H2AX after
exposure to etoposide, a potent DNA damaging drug.
The confocal analysis (Figure 1c) revealed that both the
cell lines with two different features of CNA and the
expression profiles at the transcript and protein levels
showed no difference in their response to DNA damage
at both the endogenous (g-H2AX staining in untreated
control cells) and exogenous levels (g-H2AX staining
after etoposide treatment), suggesting that the inherent
tendency of CNA and corresponding expression were
independent of the DNA damage response (DDR),
which was equal. We nevertheless were still confronted
with the problem of noncorrespondence of the H2AFX
gene copy number with its transcript level and therefore
analyzed the expression of miR-24-2, another regulatory
control for H2AFX gene expression. A bioinformatics
search for possible miR regulation using four bioinfor-
matics tools (miRanda[36], microCosm targets[37], Pic-
Tar[33] and Target Scan[35]) indicated miR-24-2 as the
most likely potential regulator of the H2AFX gene
(Table S1 in Additional file 1). Also, during the course
of this study, a report experimentally validated the miR-
24-2-mediated downregulation of H2AX in terminally
differentiated mammalian cells [26].
miR-24-2 expression in the two model cell lines
We examined the expression of miR-24-2 by RT-PCR
analysis that uncovered 14-fold higher miR-24-2
levels in HeLa cells than in MCF-7 cells (Figure 1d).
This observation provided an explanation for the
ambiguity observed in experiments between gene
copy number and transcript status of MCF-7 and
HeLa cells. It is likely that the expression in MCF-7
cells was high because of the low level of miR-24-2
present in these cells, resulting in lower transcrip-
tional degradation of H2AX mRNA and therefore not
corresponding with the CNA status. Higher levels of
miR-24-2 in HeLa cells, on the other hand, allowed
destabilization of a larger fraction of the synthesized
mRNA, resulting in the detection of lower expression
of the transcripts.
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carcinoma samples
The analysis of the two cell lines, MCF-7 and HeLa,
s u g g e s t e dt h a ta l t e r a t i o ni nH2AFX gene copy number
does not directly regulate its expression; instead, the
expression is more strongly controlled by a miR, hsa-
miR-24-2. To corroborate the above observations, we
repeated the same analysis in sporadic breast tumor
samples that also exhibited alteration in H2AFX gene
copy number. Breast cancer samples (36 pairs) belong-
ing to stages I, II and III showed an alteration in gene
c o p yn u m b e ri n2 2 %( 8o f3 6 )o fc a s e s ,w h i c hi n v o l v e d
both amplification and deletion when compared to
normal samples. The deletion accounted for 8.3% (3 of
36) of the cases and amplification in about 13.8% (5 of
36) of samples (Figure 2a). The tumors from these
samples were subjected to real-time transcript analysis
using TaqMan chemistry. geNorm software was used
to establish the two most stable internal control genes
(MRPL19 and PUM1) from a group of four endogen-
ous controls (ACTIN, GAPDH, PUM1 and MRPL19),
followed by the calculation of the normalization factor
f o re a c ht i s s u es a m p l e( T a b l eS 2i nA d d i t i o n a lf i l e1 ) .
I tw a so b s e r v e dt h a to fe i g h ts a m p l e ss h o w i n gg e n o m i c
copy number alteration (CNA), only one (sample 25)
showed correspondence with the transcript level. Seven
other samples with either deletion or amplification did
not show any parallel between the gene CNA and tran-
scriptional status (Figure 2b). As observed in cell lines,
the studied tumor samples also showed a noncorre-
spondence between CNA and transcript expression. To
examine whether H2AX gene expression in tumor tis-
sues also corresponds negatively with miR-24-2 expres-
sion, the paired tumor samples were examined for
miR-24-2 expression in 33 tumor samples and 13 nor-
mal breast tissue samples. miR-145, a known miR that
is downregulated in breast cancers, and RNU-44 as an
endogenous miR, were used as controls. As expected,
Figure 1 Comparison of H2AFX status in MCF-7 vs. HeLa cells. (a) Real-time polymerase chain reaction analysis of gene copy number
between the two cell lines using RNase P as an endogenous control. (b) Comparison of transcript expression using TaqMan assay for H2AX
(Hs01573336_s1). (c) Confocal images of subcellular localization of H2AX and g-H2AX before and after etoposide (10 μmol/l) treatment. (d) Fold
difference in hsa-miR-24-2 expression using RNU 44 (Assay ID 001094; PN 4427975) for normalization. PI, propidium iodide.
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but miR-24-2 showed differential status with respect to
different stages of tumors (Figures S1a and S1b in
Additional file 2). Compared to corresponding normal
tissue samples, miR-24-2 was low in tumors and was
relatively higher in stage I and lower in stages II and
III tumor tissue samples, with an inverse relation
between mir-24-2 and H2AX mRNA expression
(Figures 3a and 3b). The expression of both the H2AX
gene and miR-24-2 in individual patients with tumors
at different stages was again observed to have an
inverse relation (Figure 3c), confirming miR-24-2 as a
strong regulator of H2AX in in vivo sporadic breast
tumors.
Figure 2 Noncorrespondence of H2AFX gene copy number and transcript expression in patients with sporadic breast cancer. (a) H2AFX
gene copy number alteration in patients with sporadic breast cancer. Patients 9 to 11 show deletion, whereas patients 24 to 28 show
amplification. A twofold change and above was considered deletion or amplification. (b) H2AFX transcript expression in patients with altered
gene copy number. Note the noncorrespondence of gene copy number and transcript expression with the exception of patient 25.
Srivastava et al. Breast Cancer Research 2011, 13:R39
http://breast-cancer-research.com/content/13/2/R39
Page 6 of 11In vitro overexpression of miR-24-2 in MCF-7 cells and
modulation of apoptotic response
To study the effect of miR-24-2 overexpression on gene
expression, MCF-7 cells were transfected with precursor
miR-24-2 oligonucleotides,a n dt h eo v e r e x p r e s s i o no f
miR-24-2 was verified by real-time TaqMan assay (Fig-
ure S2 in Additional file 2). Downregulation of H2AX
expression in miR-24-2-overexpressing cells confirmed
H2AX as a cellular target of miR-24-2 (Figure 4a). Inter-
estingly, overexpression of miR-24-2 also resulted in
increased apoptotic cell death as assayed by annexin V
staining. This effect of miR-24-2 overexpression was
further evident in response to the DNA damaging drug
cisplatin (200 μmol/l), as well as to hydrogen peroxide
(25 mmol/l), as compared to untransfected and negative
precursor oligonucleotide (AM17110; Ambion) trans-
fected controls (Figures 4b and 4c). The observed hyper-
sensitivity to drugs, increased apoptosis and decreased
H2AX expression in cells over-expressing miR-24-2
indicated a possible role of H2AX in regulating apopto-
sis. In this context, it is interesting to note that
phosphorylation of tyrosine 142 residue of H2AX has
been shown to modulate a cell’s decision to enter into
the apoptotic or survival pathway [38,39]. Also, it could
be possible that in addition to H2AX, miR-24-2 regu-
lates other key genes of the apoptotic pathway. To test
this possibility, we analyzed the expression of key apop-
totic and DDR genes (B R C A 1 ,B R C A 2 ,A T M ,M D M 2 ,
T P 5 3 ,C H E K 2 ,C Y T - C ,B C L - 2and P21)i nc e l l sa f t e r
overexpression of miR-24-2 (Figure 4a). The transcript
expression of H2AFX, BCL-2, MDM2 and P21 were sig-
nificantly reduced and therefore suggested that BCL-2,
MDM2 and p21 could possibly be the cellular targets of
miR-24-2. Intriguingly, the bioinformatics analysis also
revealed the presence of miR-24-2 binding sites in BCL-
2 and MDM2 mRNA besides having two binding sites
in H2AFX mRNA (Figure S3 in Additional File 2), how-
ever, the binding site could not be identified in P21
mRNA. We further tested the gene expression in MCF-
7 cells transfected with miR-24-2-specific antagomirs,
and it was observed that inhibiting miR-24-2 expression
resulted in significantlye n h a n c e de x p r e s s i o no fBCL-2
Figure 3 Analysis of microRNA (miR) hsa-miR-24-2 expression level in sporadic breast cancer samples of different stages (stages I, II
and III) and its correlation with H2AX transcript expression. (a) H2AX transcript expression. (b) miR-24-2 expression. (c) Individual patient-
wise comparison of H2AX transcript and miR-24-2 expression in representative breast tumor samples of stage I (n = 3), stage II (n = 2) and stage
III (n = 3).
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(Figure S7 in Additional file 2). The study therefore
suggested BCL-2 as a possible novel cellular target of
miR-24-2 and confirmed H2AX regulation by miR-24-2
in proliferating cell lines and in tumor samples.
miR-24 regulates BCL-2 gene by binding to the predicted
3’UTR sites
BCL-2 is a known antiapoptotic gene. To confirm the
presence of a putative binding site for miR-24-2 within
the 3’UTR region of the BCL-2 gene, the specific pri-
mers flanking the binding sites were designed and the
resulting amplicon was cloned into the 3’UTR region of
the luciferase gene of the reporter vector pGL3 (pGL3/
BCL-2). H2AX, known to be regulated by miR-24-2, was
used as a positive control for the luciferase assay. The
luciferase reporter vectors were co-transfected into
M C F - 7a n dH e p G 2c e l l sw i t hp E P - m i R - 2 4 - 2v e c t o r .
Subsequently, luciferase activity was measured. It was
observed that overexpression of miR-24-2 was able to
decrease the luciferase activity of the reporter vector
containing BCL-2/H2AFX miR-24-2 binding sites
(Figure 4d). These data showed that miR-24-2 could
downregulate its targets, BCL-2 and H2AFX,b yb i n d i n g
Figure 4 miR-24-2 overexpression and its effect on gene expression and cell proliferation. (a) Effect of miR-24-2 upregulation on gene
expression profile of MCF-7 cells for TP53, ATM, P21, MDM2, CHEK2, H2AFX, CYT-C, BCL-2, BRCA1 and BRCA2. (b) miR-24-2 overexpressing MCF-7
cells treated with cisplatin (200 μmol/l) and assayed for apoptotic cell death using annexin V staining and fluorescence-activated cell sorting
analysis. (c) miR-24-2-overexpressing MCF-7 cells treated with H2O2 (25 mmol/l) and analyzed for apoptosis. (1) Negative control (unstained MCF-
7 cells), (2) MCF-7 control cells, (3) MCF-7 + mock transfection, (4) MCF-7 + miR-24-2 transfection, (5) MCF-7 + H2O2/cisplatin, (6) MCF-7 + mock
transfection + H2O2/cisplatin and (7) MCF-7 + miR-24-2 transfection + H2O2/cisplatin. The extent of apoptosis was quantified as percentage of
annexin V-positive cells. Error bars indicate standard deviation. (d) Luciferase expression in MCF-7 cells overexpressing miR-24-2 and transfected
with pGL3 control vector or vector harboring the predicted miR-24-2 binding site present in 3’UTR of H2AFX/BCL-2 genes. (e) Proposed model of
miR-24-2-mediated apoptotic induction. Following overexpression of miR-24-2, the mRNA expression of key apoptotic (BCL-2 and MDM2)/DNA
damage response genes (H2AFX and P21) is downregulated. While downregulation of H2AX would lead to impaired DNA repair and loss of cell-
cycle arrest, reduced expression of p21 prevents entry into cycle arrest pathway and instead signals the apoptotic pathway. Reduced BCL-2 and
MDM2 expression is capable of directly inducing the apoptotic pathways leading to cell death.
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mechanistic insight into the apoptotic induction caused
by its overexpression.
Discussion
The observations made in this study suggest that the
H2AFX gene undergoes CNA in patients with sporadic
breast cancer, as well as in studied cancer cell lines;
however, the expression status does not correspond with
the CNA status. Two recent studies in rats and mice at
a genome-wide scale have described the effect of CNVs
on gene expression, exhibiting negative correlation in
2% to 15% of the genes with their expression [3,4]. We
provide evidence for one of the possible mechanisms of
such a nonconcordant relation between expression and
the number of gene copies based on specific miR regula-
tion of expression. One such miR, hsa-miR-24-2, that
has been reported to be a strong regulator of H2AX
expression [24] was confirmed in our study, both in cell
lines and in sporadic breast tumor samples, irrespective
of CNA. Interestingly, it was observed that overexpres-
sion of miR-24-2 downregulated the transcript expres-
sion of H2AFX alongwith BCL-2, MDM2and P21, with a
corresponding increase in apoptotic cell death, suggest-
ing an adoption of a new paradigm in therapeutic
designs to overcome apoptotic resistance in cancer cells.
T h er o l eo fm i R - 2 4 - 2i nr e g u l a t i o no fa p o p t o s i sh a s
been shown by a few studies, but the regulation of pro-
or antiapoptotic genes by this miR is not known, except
for FAF1 [30]. Our study provides the mechanistic
insight into the apoptotic induction mediated by miR-
24-2 and identifies BCL-2 as the novel cellular target of
miR-24-2 (Figure 4e). We propose that while downregu-
lation of H2AX results in impaired DNA repair, chan-
neling the cells into the apoptotic pathway,
downregulated BCL-2, encoding an integral outer mito-
chondrial membrane protein and known to block the
apoptotic death in a variety of cell systems [40], could
contribute further to apoptotic cell death [41]. It has
been shown that H2AX is required for the p53/p21
pathway [42], and it is expected that the lower level of
H2AX expression could prevent the cells from cell cycle
arrest and promote induction of apoptosis. We have
also observed that MDM2 and P21 possibly could
emerge as other key genes that promote apoptotic
induction and whose expression is modulated by miR-
24-2, either directly or indirectly. This, however, would
require experimental confirmation through reporter
gene assays in future studies. Nevertheless, on the basis
of our findings, we propose that miR-24-2 is a strong
inducer of apoptotic pathway in MCF-7 cells by control-
ling the expression of important genes involved in apop-
totic regulation. MDM2 and p21 are known as key
players in regulating the p53 response to induce
apoptosis or growth arrest [43]. MDM2 acts as an onco-
protein that promotes cell survival and cell cycle pro-
gression by inhibiting the p53 tumor suppressor protein
[44]. Also, low levels of MDM2 have been shown to
induce the transcription of proapoptotic genes and the
translocation of p53 from nucleus to mitochondria,
resulting in apoptosis [45]. p21 is a cyclin-dependent
kinase inhibitor (CDKN1A) and functions as a regulator
of cell cycle progression to G1 in response to p53
checkpoint pathway [46]. Its role in apoptosis is not
very clear, but the possibility is that low expression of
p21 would prevent the cells from p53/p21-mediated cell
cycle arrest pathway and result in induction of apoptosis
[47]. Since p21 transcripts do not have a miR-24-2 bind-
ing site, we surmise that the expression of p21 gets
reduced as a result of secondary effect and could possi-
bly be a secondary target of miR-24-2 [48]. Interestingly,
we have also tested the apoptotic potentiating activity of
miR-24-2 in the presence of a mitotic inhibitor drug,
docetaxel, and observed a significant increase in cell
death in MCF7 cells that have received combination
treatmentof docetaxel (2 nmol/l) and miR-24-2 over-
expression (500 ng of pEP-miR-24-2) as compared to
MCF7 cells that have received docetaxel treatment or
mir-24-2 over-expression alone (data not shown). We
propose that the lower expression of these genes as a
result of miR-24-2 overexpression could independently,
or in association with other proteins, target different
apoptotic pathways and provide an alternative window
for effective tumor cell killing, either alone or in combi-
nation with anticancer drugs such as cisplatin and
docetaxel.
Conclusions
This study provides the evidence for a role of miR-24-2
in guiding H2AFX gene expression in the background of
the differential status of gene copy number. Further-
more, the study identifies the antiapoptotic gene BCL-2
as a novel cellular target of miR-24-2 and thereby pro-
vides a mechanistic insight into the apoptotic induction
caused by miR-24-2 overexpression in mammalian cells.
We propose that miR-24-2 alone or in combination
with anticancer drugs holds strong potential for thera-
peutic killing of cancer cells.
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